Gene-expression profiling in human cutaneous melanoma
- 19 May 2003
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 22 (20) , 3076-3080
- https://doi.org/10.1038/sj.onc.1206448
Abstract
Genomic technology presents new and exciting opportunities to study complex human diseases. Several types of genomic analysis are helping to elucidate the biology of important human cancers. One of these, gene expression profiling, provides a more comprehensive view of the consequences of the genetic changes in cancer cells than was previously available. In addition to detailing the expression patterns of thousands of genes simultaneously, this exploding field of research has begun to build a new ‘molecular taxonomy’ of cancer and to identify novel disease genes for many human cancers, including cutaneous melanoma. Whether this new information will lead to improved treatments and prolonged survival for cancer patients remains to be determined. Here, we review the use of complementary DNA microarray technology to study gene expression patterns in cutaneous melanoma and highlight recent advances concerning the identification of novel melanoma disease-related genes. The fundamentals of microarray technology and analysis have been extensively discussed, and readers are referred to several recent reviews in this area.Keywords
This publication has 28 references indexed in Scilit:
- Mutations of the BRAF gene in human cancerNature, 2002
- RHO–GTPases and cancerNature Reviews Cancer, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Computational analysis of microarray dataNature Reviews Genetics, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Activation of Protein Kinase D by Signaling through the α Subunit of the Heterotrimeric G Protein GqPublished by Elsevier ,2000
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985